While on Capitol Hill the new Congress begins to take on the pharmaceuticals industry, the healthcare investment community is holding its annual confab in the hills of San Francisco--House Speaker Nancy Pelosi's home district.
I'm at the 25th Annual JPMorgan Healthcare Conference at the Westin St. Francis on Union Square. The four-day event is just getting started, but the halls are already jam packed every half hour as the thousands of investors here move from one company presentation to the next.
The conference opened with at least a few companies making news: Genentech doing a deal with Seattle Genetics , ImClone Systems pulling out of the conference at the last minute because it will announce late-stage data sometime this week on its drug Erbitux for previously untreated colorectal cancer that has spread, and Mylan Labs announcing it has closed its acquisition of an Indian company--just to name a few.
We will kick off our coverage this afternoon with a live interview with today's lunchtime keynoter, Dr. Mark McClellan--the former FDA Commissioner and Administrator of Medicare and Medicaid Services. That's on "Closing Bell" at 4 p.m. ET.
Then tomorrow we've got a full slate of CEOs. Eight in all. Starting on "Squawk Box" at 8 a.m. ET. Among our guests: the chiefs of Celgene , Amylin Pharmaceuticals , Mylan, and Biogen Idec . I'll be doing live interviews from here throughout the day tomorrow on every CNBC business-day show.
Off to catch Amylin's presentation right now and then Dr. McClellan's speech.
We'll see if more news about the industry comes out of the first 100 hours on the Hill or out of the 33 hours of the JPMorgan Healthcare Conference in the hills of San Francisco.
Questions? Comments? Pharma@cnbc.com